ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-HER2/Topoisomerase I Inhibitor ADC GQ1005

Its studies are mostly in Breast Neoplasms, led by GeneQuantum Healthcare (Suzhou).

Furthest: phase 3, since Jun 17, 20262 company-led studies, 2 open or runningNext primary completion: Jan 9, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GeneQuantum Healthcare (Suzhou)22 open or runningphase 3since Jun 17, 2026Nov 23, 2023Jan 9, 2027phase 3 · NCT07673029

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 23, 2023First study: phase 1 study in HER2 Expressing or Mutated Advanced Malignant Solid TumorsFirst studyNCT06154343 · 150 planned · China
  2. Jun 17, 2026Phase 3 study in HER2-positive Breast CancerPhase 3 reachedNCT07673029 · 228 planned · China

Ahead

  1. Jan 9, 2027Primary completion: phase 3 study in HER2-positive Breast CancerNCT07673029

TargetBeta

ERBB2 →read by rule
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) ”NCIt, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07673029HER2-positive Breast Cancer · China3RecruitingJan 9, 2027228
NCT06154343HER2 Expressing or Mutated Advanced Malignant Solid Tumors · China1RecruitingDec 31, 2024150

How it is read

Names in the registry

  • “GQ1005”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.